SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs strong third-quarter results and rapid growth in its Quake AI GPU-cloud business are driving attention as the companys AI-infrastructure pivot gains traction. Bulls point to improving operations and the Anthropic-linked expansion, while skeptics focus on losses, cash needs and financing risks; short-squeeze claims remain speculation.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million.
Fractyl Health (NASDAQ:GUTS) stockread more...

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers

Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million.
Nkarta (NASDAQ:NKTX) stock increased byread more...

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology...

Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future

Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the FuturePR NewswireNEWTON, Mass., Nov. 2, 2026 The Company Remains Focused on Supporting...

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNEWTON, Mass., Oct. 1, 2026NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Sept. 1, 2026 NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PR Newswire NEWTON, Mass...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 20, 2026 NEW YORK, Aug. 20, 2026...

• Reported GAAP EPS of -$2.32 up 46.30% YoY
• Reported revenue of $33.43M down -11.86% YoY

Karyopharm Therapeutics Inc. faces substantial doubt regarding its ability to continue as a going concern, with liquidity concerns following upcoming debt payments and recent clinical trial failures for its lead asset.

Karyopharm Therapeutics Inc. reported positive clinical results for its myelofibrosis program, supporting a planned sNDA submission in August 2026, alongside an 18% year-over-year increase in net product revenue for the period.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Why Is KPTI Stock Down 69% After-Hours Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer.</li><li>Company officials said they were disappointed by the unexpected outcome and will cut planned spending on the endometrial cancer program.</li><li>Chief Executive Richard Paulson said that the company remains focused on its myelofibrosis program.</li></ul> Shares of Karyopharm Therapeutics (KPTI) fell 69% in after-hours trading on Thursday after the biotech company reported that its drug selinexor failed to delay disease progression meaningfully in endometrial cancer in a late-stage clinical trial. &nbsp;<h2 class="st-heading-2">What Did The Trial Show?</h2>The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer. It did not show a statistically significant delay in disease progression. A trend toward longer progression-free survival was seen in a key patient group—roughly 13 months for those on selinexor versus about 7.5 months on placebo—but the difference did not reach the required threshold for success, the company said.Safety results matched the drug’s known profile, the company said, with no new concerns identified. Company officials said they were disappointed by the unexpected outcome and will cut planned spending on the endometrial cancer program while completing a full data review for presentation at a future medical meeting. They plan to keep following patients for longer-term survival results.<h2 class="st-heading-2">KPTI’s Steps Ahead</h2>“While the results we are announcing today fell short of our expectations, they do not diminish our confidence in the broader potential of selinexor,” said Chief Executive Richard Paulson. He added that the company remains focused on its myelofibrosis program.In a separate announcement the same day, Karyopharm said it plans to submit an application to the U.S. Food and Drug Administration in August seeking accelerated approval for selinexor combined with ruxolitinib as a treatment for myelofibrosis. If cleared, the combination could become the first approved dual therapy for the rare blood cancer. The company intends to request priority review, which could lead to a decision about six months after submission.Paulson called the planned filing a potentially transformative step for patients and for the company.Selinexor, sold as Xpovio, is already FDA-approved for treating multiple myeloma in certain adult patients. Karyopharm reported U.S. XPOVIO (selinexor) net product revenue of $114.9 million for the full year 2025, accounting for a major portion of the company’s overall revenue. &nbsp;However, earlier this year, the FDA withdrew selinexor’s accelerated approval for a type of lymphoma after Karyopharm did not complete a required confirmatory trial, reducing its total addressable market.<h2 class="st-heading-2">How Did KPTI Retail Traders React?</h2>On Stocktwits, retail sentiment around KPTI rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume stayed at normal levels.A Stocktwits user said that partnerships may help the company continue its pipeline efforts.<stembedurl>https://www.stocktwits.com/joe77w/message/660525957</stembedurl>Another dismissed the after-hours selloff, noting that the company already has approvals in place and a remaining pipeline.<stembedurl>https://www.stocktwits.com/Tea_n_crumpet_enjoyer/message/660523869</stembedurl><a href="https://stocktwits.com/symbol/KPTI">KPTI stock</a> has fallen 5% year-to-date.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/phat-stock-clocks-worst-day-in-over-1-5-years-what-sparked-the-selloff/cZN5iRSRJ2B">PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer.Company officials said they were disappointed by the unexpected outcome and will cut planned spen

Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal. 


iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.0174
Prev Close	$0.04
Open	$0.0292
Dividend Yield	0.00%
50-Day Moving Average	$0.8876
Beta	1.32
Avg. Volume	4.58M
PE Ratio	0.00

52-Week High	$10.99
52-Week Low	$0.008
Market Capitalization	$578,377.00
EPS (Annual)	-$17.93
Price to Book	-0.00
Revenue Per Employee	$640,644.74

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPTI Fundamentals